Good morning. We have a new investigation out today about how Mount Sinai in New York mounted an aggressive campaign to stifle debate over its controversial brain research. Check it out here.
And let’s get into the biotech news.
The need-to-know this morning
- A marketing application for a new type of non-opioid pain medication developed by Vertex Pharmaceuticals was accepted by the FDA, with an approval decision data set for Jan. 30, 2025.
- GSK reported second-quarter earnings.
- Fibrogen reported negative outcomes from two clinical trials in pancreatic cancer. The company said it will discontinue development of the drug, called pamrevlumab, and reduce its workforce by 75%.
Eisai, Biogen argue for long-term use of Leqembi
Eisai and Biogen reported new results showing that early Alzheimer’s patients treated with Leqembi up to three years experienced less cognitive decline than what’s expected of untreated patients based on historical data. The manufacturers said the data support long-term, continuous use of the drug.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect